Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients

Universa Medicina · Vol. 35 No. 3 (2016) · hlm. 165–170

DOI
10.18051/UnivMed.2016.v35.165-170
ISSN
2407-2230, 1907-3062
Terbit
2016-11-30
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng

Abstrak

BackgroundEpithelial ovarian cancer (EOC) is one of the most common cancers diagnosed in Indonesian women. A combination of paclitaxel and carboplatin is used to treat EOC as standard chemotherapy which is known to have hematologic toxicities. This study aimed to investigate the effect of combined paclitaxel-carboplatin chemotherapy on hematologic status in EOC patients managed at Dr. Hasan Sadikin General Hospital, Bandung, West Java.MethodsAll patients with confirmed pathological diagnosis of EOC at Dr. Hasan Sadikin General Hospital in the period of 2013 to 2014 were registered. Only patients with complete hematologic data before and after chemotherapy were collected and compared using the paired non-parametric Wilcoxon and McNemar tests. ResultsIn total there were 147 patients with EOC (median age 46 ± 12 years), with the most dominant pathological diagnosis of mucinous (32.7%) and serous (29.3%) types. Only 33 patients had hematologic data before the initiation of chemotherapy. There was a significant decrease after chemotherapy including hemoglobin level (12.0 vs 10.9 g/dL, p=0.013), erythrocyte count (4.53 vs 3.74 million/mL, p<0.001), leukocyte count (7,700 vs 4,000/mm3 p<0.001) and platelet count (343,000 vs 215,000/mm3, p<0.001). Interestingly, anemia cases after chemotherapy were predominant (87.9%) compared with erythopenia, leukopenia, thrombocytopenia i.e. 39.4%, 57.6%, and 27.3% respectively. ConclusionsThis study confirmed the hematologic toxicities after paclitaxel-carboplatin chemotherapy in EOC patients treated in Hasan Sadikin General Hospital, West Java. The hemoglobin concentration may serve as prognostic factor. Further studies directed to other factors such as genetic factor for polymorphisms may be encouraged to explore the decrease of the hematologic indices.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 178 tautan kepenulisan bersama · 37 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Padjadjaran University
  • Dr. Hasan Sadikin General Hospital
  • Sumatera Institute of Technology
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Ika Agus RiniSumatera Institute of Technology6
Ramdan PanigoroPadjadjaran University5
Ani Melani MaskoenPadjadjaran University5
Gita Widya PradiniPadjadjaran University5
Bethy Suryawathy HernowoDr. Hasan Sadikin General Hospital3
Maringan Diapari Lumban TobingDr. Hasan Sadikin General Hospital3
Laniyati HamijoyoDr. Hasan Sadikin General Hospital2
Lelani ReniartiDr. Hasan Sadikin General Hospital2
Kevin Dominique TjandraprawiraPadjadjaran University2
Yudi Mulyana HidayatDr. Hasan Sadikin General Hospital2
Samsudin SurialagaPadjadjaran University2
Afini Tiara ResiPadjadjaran University1
Yuna Islamiati IslamiatiPadjadjaran University1
Shofia Dewi Fortuna FortunaPadjadjaran University1
Jessica Hamriani HamrianiPadjadjaran University1
Adhilizha Zumrotul Khasanah KhasanahPadjadjaran University1
Amira Husna Bestari BestariPadjadjaran University1
Muhammad Azka Arrazi ArraziPadjadjaran University1
Nevita Naira Dyahrani DyahraniPadjadjaran University1
Rania Ziamayra ZiamayraPadjadjaran University1
Muhammad Dzakwan Farisi FarisiPadjadjaran University1
Adika Ruhani Satiadi SatiadiPadjadjaran University1
Deasty Dini Imara ImaraPadjadjaran University1
Dikdik KurniaPadjadjaran University1
Muhammad Hasan BashariPadjadjaran University1
Eveline YuniartiPadjadjaran University1
Tenny PutriPadjadjaran University1
Nurul QomarillaPadjadjaran University1
Mieke Hermiawati SatariPadjadjaran University1
Fathul HudaPadjadjaran University1
Julius Broto DewantoPadjadjaran University1
Haryono TansahPadjadjaran University1
Sari Puspa DewiPadjadjaran University1
Helena NapituPadjadjaran University1
Nico NagelkerkeAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients</dc:title>
	<dc:creator xml:lang="en">Charles, Afandi</dc:creator>
	<dc:creator xml:lang="en">Dewayani, Birgitta M.</dc:creator>
	<dc:creator xml:lang="en">Sahiratmadja, Edhyana</dc:creator>
	<dc:creator xml:lang="en">Winarno, Gatot N.A.</dc:creator>
	<dc:creator xml:lang="en">Susanto, Herman</dc:creator>
	<dc:subject xml:lang="en">Anemia</dc:subject>
	<dc:subject xml:lang="en">erythropenia</dc:subject>
	<dc:subject xml:lang="en">leukopenia</dc:subject>
	<dc:subject xml:lang="en">thrombocytopenia</dc:subject>
	<dc:subject xml:lang="en">epithelial ovarian cancer</dc:subject>
	<dc:subject xml:lang="en">paclitaxel-carboplatin</dc:subject>
	<dc:description xml:lang="en">BackgroundEpithelial ovarian cancer (EOC) is one of the most common cancers diagnosed in Indonesian women. A combination of paclitaxel and carboplatin is used to treat EOC as standard chemotherapy which is known to have hematologic toxicities. This study aimed to investigate the effect of combined paclitaxel-carboplatin chemotherapy on hematologic status in EOC patients managed at Dr. Hasan Sadikin General Hospital, Bandung, West Java.MethodsAll patients with confirmed pathological diagnosis of EOC at Dr. Hasan Sadikin General Hospital in the period of 2013 to 2014 were registered. Only patients with complete hematologic data before and after chemotherapy were collected and compared using the paired non-parametric Wilcoxon and McNemar tests. ResultsIn total there were 147 patients with EOC (median age 46 ± 12 years), with the most dominant pathological diagnosis of mucinous (32.7%) and serous (29.3%) types. Only 33 patients had hematologic data before the initiation of chemotherapy. There was a significant decrease after chemotherapy including hemoglobin level (12.0 vs 10.9 g/dL, p=0.013), erythrocyte count (4.53 vs 3.74 million/mL, p&amp;lt;0.001), leukocyte count (7,700 vs 4,000/mm3 p&amp;lt;0.001) and platelet count (343,000 vs 215,000/mm3, p&amp;lt;0.001). Interestingly, anemia cases after chemotherapy were predominant (87.9%) compared with erythopenia, leukopenia, thrombocytopenia i.e. 39.4%, 57.6%, and 27.3% respectively. ConclusionsThis study confirmed the hematologic toxicities after paclitaxel-carboplatin chemotherapy in EOC patients treated in Hasan Sadikin General Hospital, West Java. The hemoglobin concentration may serve as prognostic factor. Further studies directed to other factors such as genetic factor for polymorphisms may be encouraged to explore the decrease of the hematologic indices.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2016-11-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/vnd.openxmlformats-officedocument.wordprocessingml.document</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/122</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2016.v35.165-170</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 35 No. 3 (2016); 165-170</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2016.v35.i3</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/122/380</dc:relation>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/122/619</dc:relation>
	<dc:relation>10.18051/univmed.v35i3.122</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2016 Afandi Charles, Birgitta M. Dewayani, Edhyana Sahiratmadja, Gatot N.A. Winarno, Herman Susanto</dc:rights>
</oai_dc:dc>